Explain the Controversy About the New Sublingual Sufentanil (Dsuvia)

March 2019

You'll hear about a new sublingual sufentanil tablet (Dsuvia, deh-SOO-vee-uh) for acute pain management.

It was initially developed for battlefield use.

But FDA approval of this potent opioid during the opioid epidemic...with its easy-to-administer dosage form...is stirring up concerns.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote